Honokiol Alleviates Cognitive Deficits of Alzheimer's Disease (PS1(V97L)) Transgenic Mice by Activating Mitochondrial SIRT3

Accumulating evidence has demonstrated that mitochondrial dysfunction is a prominent early event in the progression of Alzheimer's disease (AD). Whether protecting mitochondrial function can reduce amyloid-beta oligomer (A beta O)-induced neurotoxicity in PS1(V97L) transgenic mice remains unknown. In this study, we examined the possible protective effects of honokiol (HKL) on mitochondrial dysfunction induced by A beta Os in neurons, and cognitive function in AD PS1(V97L)transgenic mice. We determined that HKL increased mitochondrial sirtuin 3 (SIRT3) expression levels and activity, which in turn markedly improved ATP production and weakened mitochondrial reactive oxygen species production. We demonstrated that the enhanced energy metabolism and attenuated oxidative stress of HKL restores A beta O-mediated mitochondrial dysfunction in vitro and in vivo. Consequently, memory deficits in the PS1(V97L) transgenic mice were rescued by HKL in the early stages. These results suggest that HKL has therapeutic potential for delaying the onset of AD symptoms by alleviating mitochondrial impairment and increasing hyperactivation of SIRT3 in the pathogenesis of preclinical AD.